In late October 2025, Bristol Myers Squibb announced positive 52-week Phase 3 data for Sotyktu in active psoriatic arthritis and long-term safety results for the drug in systemic lupus erythematosus, ...
Source LinkIn late October 2025, Bristol Myers Squibb announced positive 52-week Phase 3 data for Sotyktu in active psoriatic arthritis and long-term safety results for the drug in systemic lupus erythematosus, ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.